Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Precision Biosciences (DTIL) Invested Capital (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Invested Capital for 8 consecutive years, with $16.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 74.36% to $16.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.6 million, a 74.36% decrease, with the full-year FY2024 number at $56.4 million, up 36.63% from a year prior.
  • Invested Capital was $16.6 million for Q3 2025 at Precision Biosciences, down from $34.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $125.1 million in Q2 2022 to a low of $16.6 million in Q3 2025.
  • A 5-year average of $70.3 million and a median of $62.4 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: surged 110.8% in 2021, then crashed 74.36% in 2025.
  • Precision Biosciences' Invested Capital stood at $93.6 million in 2021, then dropped by 11.74% to $82.7 million in 2022, then plummeted by 50.07% to $41.3 million in 2023, then surged by 36.63% to $56.4 million in 2024, then plummeted by 70.5% to $16.6 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Invested Capital are $16.6 million (Q3 2025), $34.1 million (Q2 2025), and $49.3 million (Q1 2025).